Symbyax ® (olanzapine and fluoxetine HCl) for the acute treatment of treatment-resistant depression

Academic Article

Abstract

  • Studies comparing Symbyax with olanzapine and fluoxetine alone were designed to reflect the population of patients with treatment-resistant depression (TRD). Individual studies varied somewhat in general design, which yielded helpful insights into which patients might benefit from this treatment. Results showed that Symbyax provided rapid symptom improvement and clinically significant remission rates. Given its reasonable tolerability and proven benefit, Symbyax is a useful new therapy for the acute treatment of TRD, defined as major depressive disorder in adult patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode.
  • Published In

    Author List

  • Shelton RC
  • Start Page

  • 20
  • End Page

  • 27
  • Volume

  • 26
  • Issue

  • SUPPL. MAY